Novel superoxide dismutases of fungal origin are active, gastric stable and thermal stable, and effective for use in animal feed additives. The use of superoxide dismutase in animal feed improve animal growth, animal health and intestinal health of animals.

The invention features compositions and methods for treating, reducing, or ameliorating the debilitating effects of Amyotrophic Lateral Sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA). Provided herein are compositions and methods of using improved new base editors (e.g., adenosine base editors) comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide to disrupt normal transcription of a gene associated with a genetic disease or condition, e.g. ALS, or SBMA by modifying a target gene associated with the genetic disorder or condition with a base editor system provided herein.

A dual functional expression vector is disclosed. The dual functional vector comprises a nucleic acid suitably configured for expressing at least two active agents, where a first active agent is an siRNA/shRNA or miRNA for silencing endogenous mRNA transcripts from an endogenous gene, where a second active agent is a translation product of an allele of the endogenous gene being silenced, where the translation product is expressed from an mRNA transcript that is insensitive to the silencing activity of the first active agent. Also describes are methods of making the dual functional expression vector and methods of using the expression vector for treatment of diseases and for generating animal models of human diseases.

The present invention relates to a composition with an antioxidant activity, comprising a first dry extract derived from plant cell cultures comprising superoxide dismutase of Sulfolobus solfataricus, a second dry extract derived from plant cell cultures comprising superoxide dismutase of Aeropyrum pernix and a third dry extract derived from plant cell cultures comprising superoxide dismutase from Deinococcus radiodurans, wherein said plant cell cultures are cultures of cells belonging to Solanum lycopersicum species.

An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3′UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3′UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.

The invention relates to an oral solution having high SOD enzymatic activity and the preparation method therefor, wherein the method comprises: pressing edible plant raw materials, followed by removing large particles by means of centrifugation (1000-4000 rpm, 0-30 min); subsequently, separating the supernatant using two processes of ultrafiltration (the first separation adopting a tubular membrane with pore size ranging from 60-120 kD; the second accomplished by an spiral-wound membrane with pore size ranging from 8-30 kD), before treated using ultra-high pressure at 200-600 MPa for a period of 1-20 min. After treated by the method of the invention, SOD has been activated with enhanced enzymatic activity up to above 10000 U/ml, which has addressed problems related to low enzymatic activity of SOD in products. The products obtained by the present method are more beneficial to human health.

A human platelet lysate preparation that contains human plasma is provided. This preparation can be generated from human platelets by concentrating and washing them under defined conditions to control the degree of human plasma present. The washed platelet concentrate is then subjected to a freeze-thaw cycle to produce platelet lysate which is centrifuged and filtered through 0.65μ, 0.45μ and 0.2μ filters, aliquoted and stored frozen at <−20° C. until thawed for use. This invention describes the novel finding that the controlled addition of human plasma to the lysate preparation significantly enhances the cell growth potency of the lysate preparation. This lysate can be used as a media supplement to replace fetal bovine serum (FBS) or other non-human serum additives used for the culture of mammalian cells. This invention also describes the formulation and use of the lysate preparation as a topical application for skin care, and wound healing, including anti-wrinkling, anti-scarring and wound resolution applications of the invention.

The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.

The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating metabolites present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level said metabolites.

A transdermal peptide with a nuclear localization ability and having an amino acid sequence as shown in SEQ ID NO: 1 is disclosed. A fusion protein including a macromolecular protein with one end being linked to the transdermal peptide is also disclosed. The transdermal peptide can be used in the preparation of a medicament or a transdermal preparation for treating skin diseases. A medicament for treating a skin disease includes the transdermal peptide and a pharmaceutically acceptable excipient. The transdermal peptide enters the cells autonomously to locate in the nuclei, and can penetrate through the stratum corneum of the skin into cells in the dermis. The peptide is conveniently synthesized artificially and suitable for transdermal administration, and has a therapeutic potential via transdermal administration by carrying a drug for treating skin diseases.